Shiksha Nation
Skip to content

Atezolizumab/hyaluronidase

Combination medication

  • 1 min read
  • 2 chapters

Explore on Lably

ToursExplore Lably’s 3D tours

The most common adverse reactions include fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite.

Atezolizumab/hyaluronidase was approved for medical use in the United States in September 2024.

Medical uses

Atezolizumab/hyaluronidase is a subcutaneous injection version of atezolizumab for all the adult indications as the intravenous formulation of atezolizumab including non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part sarcoma.

Sign up free to read the rest

One more chapter is free with a Lably account.

Already have an account?

More in Health